UK-pharmaceutical company GlaxoSmithKline (GSK) has joined with France-based venture capital investment firm Kurma Life Sciences Partners, bpifrance (France’s public investment bank), Idinvest Partners and investment fund New Enterprise Associates to launch Kurma Biofund II: The Orphan Initiative.  The first closing of the fund has reached €44m ($58.2m) out of a target total of €75m ($99.3m).

The fund will invest in treatments and innovations within the field of rare diseases, of which there are 6000 – 7000, affecting 1 in 2000 people or fewer, according to GSK.

Mouncef Slaoui, director of research and development at GSK, said: “The participation of GSK in the Kurma Biofund II continues our long term commitment to meeting the needs of patients suffering rare diseases.”

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?